SUMMARY: The preparation, purification and properties of cholera toxin type 2 are described. When the toxin was given to experimental animals it induced a high level of toxin-neutralizing antibodies. Cholera toxoid given to human volunteers induced antibodies consisting of agglutinins, vibriocidal and toxin-neutralizing antibodies. The relevant titres depended on the purity of the antigen administered.
AzurinJ. C.,
CruzA.,
PesiganT. P.,
AlveroM.,
CamenaT.,
SuplidoR.,
LedesmaL.,
GomezC. Z.1967; A controlled field trial of the effectiveness of cholera and cholera el tor vaccines in the Philippines.. Bulletin World Health Organization 37:703–727
BenensonA. S.,
AnisaSaad,
MosleyW. H.1968a; Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique.. Bulletin World Health Organization 38:277–285
BenensonA. S.,
MosleyW. H.,
FahimuddinM.,
OseasohnR. O.1968b; Cholera vaccine field trials in East Pakistan. 2. Effectiveness in the field.. Bulletin World Health Organization 38:359–372
CraigJ. P.1965; A permeability factor (toxin) found in cholera stools and culture filtrates and its neutralization by convalescent cholera sera.. Nature, London 207:614–616
DuttaN. K.,
HabbuM. K.1955; Experimental cholera in infant rabbits: a method for chemotherapeutic investigation.. British Journal of Pharmacology 10:153–159
FinkelsteinR. A.1962; Vibriocidal antibody inhibition (VAI) analysis: a technique for the identification of the predominant vibriocidal antibodies in serum and for the detection and identification of Vibrio cholerae antigens.. Journal of Immunobiology 89:264–271
FinkelsteinR. A.,
NorrisH. T.,
DuttaN. K.1964; Pathogenesis of experimental cholera in infant rabbits. I. Observations on the intra-intestinal infection and experimental cholera produced with cell-free products.. Journal of Infectious Diseases 114:203–216
FinkelsteinR. A.,
AtthasampunnaP.,
ChulasamayaM.,
CharunmetheeP.1966; Pathogenesis of experimental cholera: biologic activities of purified procholeragen A.. Journal of Immunology 96:440–449
MosleyW. H.,
McCormackW. M.,
FahimuddinM.,
AzizK. M. A.,
MizanurRahmanA. S. M.,
AlauddinChowduryA. K. M.,
MartinA. R.,
FeeleyJ. C.,
PhillipsR. A.1969; Report of the 1966–67 cholera vaccine field trial in rural East Pakistan. 1. Study, design and results of the first year of observations.. Bulletin World Health Organization 40:177–185
UngarJ.,
ChariatteN.,
StanicM.,
VarallyayS.1969; Studies on cholera. (Xth International Congress for Microbiological Standardization, Prague, 1967.). Progress in Immunobiological Standardization 3:357–362
WatanabeY.,
VerweyW. F.1965; Protective antigens from el tor vibrios. 1. The preparation and properties of a purified protective antigen from an el tor vibrio (ogawa subtype).. Bulletin of the World Health Organization 32:809–821